21 December 2023 in Real-World Data & Evidence
This guidance provides recommendations to sponsors and investigators considering the use of externally controlled clinical trials to provide evidence of the safety and effectiveness of a drug product. In an externally controlled trial, outcomes in participants receiving the test treatment according to a protocol are compared with outcomes in a group of people external to the trial who had not received the same treatment. The external control arm can be a group of people, treated or untreated, from an earlier time (historical control), or it can be a group of people, treated or untreated, during the same period (concurrent control) but in another setting. The guidance addresses considerations for the design and analysis of externally controlled trials to study the effectiveness and safety of drugs, including discussion of threats to the validity of trial results from potential bias. Although various sources of data can serve as the control arm in an externally controlled trial, this guidance focuses on the use of patient-level data from other clinical trials or from real-world data (RWD) sources, such as registries, electronic health records, and medical claims. The guidance also describes considerations related to communicating with the FDA and ensuring access by the FDA to data from an externally controlled trial. This guidance does not address other types of external controls, such as using summary-level estimates instead of patient-level data. This guidance does not discuss details of the design and analysis of a natural history study nor the reliability and relevance of various sources of RWD that could be used in an externally controlled trial. Finally, this guidance also does not discuss considerations for using external control data to supplement a control arm in a traditional randomized controlled clinical trial. In general, FDA guidance documents do not establish legally enforceable responsibilities. Instead, guidance describes the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance means that something is suggested or recommended, but not required.
24 January 2023 in Real-World Data & Evidence
This article provides a brief overview of the key aspects of planning, conducting, and reporting NICE clinical practice data collection and analysis studies, as well as general information about the sources of real-world data (RWD) and their use in NICE management decision-making algorithms. The difficulties of finding and using RWD are described, as well as methods for overcoming them, brief NICE recommendations for assessing the suitability of data and an algorithm for conducting quantitative studies to collect evidence from RWD are given.
2 July 2024 in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
Relevance. Clinical pharmacology is a rapidly evolving field of medicine. The advent of modern technologies has led. The continued evolution of clinical pharmacology, as reflected in publications in specialized medical journals.The aim of this study was to determine how new trends in clinical pharmacology were reflected in the publications of the leading clinical pharmacology journals in Russia during the period from 2015-2021, to conduct a comparative analysis of trends with international journals from 2015-2021.Materials and methods. Original articles published in leading Russian journals were analyzed and categorized into relevant key areas of interest, drug modalities, and therapeutic areas based on the content of the publications independently by three authors. Publications in which authors expressed divergent opinions were discussed until consensus was reached using a modified Delphi method. A comparative analysis was then performed with the results of a similar analysis published in journal “Clinical Pharmacology and Therapeutics”.Results. Most Russian journals and publications have focused on real-world data. The topics most frequently covered in international journals were pharmacometrics, machine learning, and pharmacogenetics. In third place were real-world data. The leading therapeutic areas represented in publications in both Russian and international journals were cardiology, oncology, and infectious diseases. Most publications have focused on various aspects of small molecule use.Conclusions. The novel trends in clinical pharmacology are reflected in the scientific articles published in specialized journals. The principal trends observed in Russian publications are consistent with international tendencies.
30 March 2024 in Real-World Data & Evidence
This review describes the basics of protein biosynthesis and RNA interference processes, discusses the useful and unique properties of siRNA therapy, its advantages and disadvantages in comparison with other gene silencing methods, provides a brief overview of technical advances and modifications of siRNA therapy, and characterizes siRNA-registered drugs and agents at different stages of clinical trials.
28 August 2023 in Real-World Data & Evidence
Signal detection is a crucial step in the discovery of post-marketing adverse drug reactions. There is a growing interest in using routinely collected data to complement established spontaneous report analyses.The aim. This work aims to systematically review the methods for drug safety signal detection using routinely collected healthcare data and their performance, both in general and for specific types of drugs and outcomes.Metodology. We conducted a systematic review following the PRISMA guidelines, and registered a protocol in PROSPERO.Results. The review included 101 articles, among which there were 39 methodological works, 25 performance assessment papers, and 24 observational studies. Methods included adaptations from those used with spontaneous reports, traditional epidemiological designs, methods specific to signal detection with real-world data. More recently, implementations of machine learning have been studied in the literature. Twenty-five studies evaluated method performances, 16 of them using the area under the curve (AUC) for a range of positive and negative controls as their main measure. Despite the likelihood that performance measurement could vary by drug-event pair, only 10 studies reported performance stratified by drugs and outcomes, in a heterogeneous manner. The replicability of the performance assessment results was limited due to lack of transparency in reporting and the lack of a gold standard reference set.
19 September 2024 in Real-World Data & Evidence
There is currently no established framework for conceptualizing or implementing drug use. These recommendations provide a framework that outlines considerations to be considered when developing definitions of drug use in real-world clinical practice. The structure is intended to aid researchers in understanding and contextualizing the findings of pharmacoepidemiological studies.